ethomersol · sovietrx dossier

identity

formula

5-ethoxy-2-ethylthiobenzimidazole

label ethomersol line actoprotector school benzimidazole programme

Same scaffold family as bemitil (2-ethylthiobenzimidazole). No PubChem CID linked on this page. No local structure PNG.

Formula text only; no molecule drawing. Archive identity plate.

Key takeaways

Ethomersol is a synthetic 5-ethoxy-2-ethylthiobenzimidazole analogue of bemitil on the Leningrad / military benzimidazole actoprotector scaffold.
Mapped findings emphasise liver regeneration after partial hepatectomy and antihypoxic comparisons with bemitil and later benzimidazole derivatives.
Corpus text records it as never commercialised. This page is a thin sibling of featured bemitil.

What it is

Ethomersol keeps the 2-ethylthiobenzimidazole core of bemitil and adds a 5-ethoxy substitution that school writing associates with a shifted hepatoregenerative profile.

It appears as a reference compound in later benzimidazole derivative screens (including thietanyl series) and in disaster-medicine / military actoprotector surveys beside bemitil.

We keep it to document the scaffold neighbourhood around the featured benzimidazole actoprotector.

What the literature describes

Themed chapters drawn only from papers already mapped on this dossier. Archive map. No medical advice.

Liver regeneration beside bemitil

Gaivoronskaya, Okovityy and co-authors (2013) compare ethomersol with bemitil on liver mass restoration and nucleic-acid content after partial hepatectomy, including combinations with a succinate ester (yakton). Synthesis treats the two benzimidazoles as comparable in that model.

Antihypoxic derivative screens

Later derivative papers use bemitil and ethomersol as reference antihypoxants when screening new benzimidazole analogues (including thietazole neighbourhood work). Condensed benzimidazole antioxidant / antihypoxic titles sit in the same scaffold cloud.

Actoprotector survey neighbourhood

Survey writing on actoprotectors in disaster and military medicine lists bemitil with ethomersol among antihypoxant tools. That is class context, not a commercialisation record.

Research trail

No PubMed or CyberLeninka chip lists were attached to this dossier in the prior map. The trail is synthesis-level Russian experimental reporting.

Featured bemitil carries the denser benzimidazole literature; ethomersol is the thin analogue entry.

Open limits

Why 5-ethoxy shifts the profile toward hepatoregeneration is thinly mechanised in open text.
Head-to-head clinical liver-disease series are not in our mapped set.
Absence of indexed PubMed rows may reflect naming variants as much as true silence.

Also on PubMed

No PubMed-indexed rows mapped for this entry in the current corpus.

Still open

Is there an English-indexed primary paper under ethomersol / etomersol spelling variants?
How does hepatoregenerative potency compare with bemitil in independent labs?
Which sulfur / ethoxy structure-activity claims survive outside originating reviews?

Reviewed against the archive corpora on 2026-09-19. Source-grounded. No clinical claims. Archive / history / research only. No medical advice. No dosing, synthesis, sourcing, or health claims.

← back to the archive